Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.

Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
Tools for Experimental
and Clinical
Immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in Cancer and
Autoimmune Diseases

Treat

Clinical Trials
to test CAR-T
and Bispecific
Antibody Strategies

Teach

Advancing
Education
and Training in
Immunotherapies

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

The SjD Map: an interactive pathway tour into Sjögren's disease signalling mechanisms.

E Silva-Saffar S, Mariette X, Gottenberg JE, Bombardieri M, Cornec D, Alarcon-Riquelme ME; PRECISEADS consortium; Barnes MR, Ng S, Ng WF, Nocturne G, Niarakis A.

NPJ Syst Biol Appl. | 2026 Mar 28. doi: 10.1038/s41540-026-00670-x. Online ahead of print. PMID: 41904187  

Evolution and prospects for the definition of clinically useful endpoints in Sjögren disease.

Beydon M, Bowman SJ, Seror R.

Curr Opin Oncol. | 2026 Feb;98:102707. doi: 10.1016/j.coi.2025.102707. Epub 2025 Dec 11. PMID: 41385979 Review.

See all Publications